Xeris Biopharma (NASDAQ:XERS) Shares Gap Up After Better-Than-Expected Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $6.12, but opened at $7.08. Xeris Biopharma shares last traded at $6.6590, with a volume of 934,999 shares.

The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 3.01%. The company had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 beat and stronger guidance — Xeris reported $0.06 EPS vs. $0.03 expected and delivered record revenue; management gave FY2026 revenue guidance of $375–$390M (above consensus), supporting upside to near‑term growth expectations. Earnings Report
• Positive Sentiment: HC Wainwright reaffirms Buy and $10 price target — The firm kept a Buy rating with a $10 PT (implying meaningful upside from current levels), which can boost investor confidence and buying interest. Analyst Note
• Neutral Sentiment: Analyst long‑term forecasts updated — HC Wainwright published multi‑year EPS projections showing a path to profitability (FY2026+ and accelerating through FY2030). These provide a roadmap for upside but are contingent on execution and product launches. Analyst Note
• Negative Sentiment: Analyst cuts to medium‑term EPS — The same HC Wainwright note trimmed FY2026–FY2029 EPS forecasts modestly (e.g., FY2027 down to $0.17 from $0.24; FY2028 and FY2029 lowered), signaling more conservative near‑to‑mid‑term profit expectations that could temper enthusiasm.
• Negative Sentiment: Patent/legal risk around Recorlev — Coverage notes that Xeris is balancing new profitability with ongoing Recorlev patent battles; adverse outcomes or prolonged litigation could pressure future sales and margins. Article on Recorlev patent issues

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on XERS shares. Oppenheimer restated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Monday. Finally, Piper Sandler raised their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.08.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total value of $120,000.00. Following the sale, the insider owned 1,685,426 shares of the company’s stock, valued at $13,483,408. The trade was a 0.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the transaction, the director directly owned 142,500 shares of the company’s stock, valued at $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 223,641 shares of company stock valued at $1,628,285 in the last quarter. 4.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new position in Xeris Biopharma during the fourth quarter worth about $84,000. VARCOV Co. acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $243,000. Virtus Investment Advisers LLC lifted its position in shares of Xeris Biopharma by 44.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock worth $291,000 after buying an additional 11,358 shares during the period. Millennium Management LLC boosted its stake in Xeris Biopharma by 63.7% in the 4th quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock valued at $6,744,000 after buying an additional 334,302 shares in the last quarter. Finally, Man Group plc acquired a new stake in Xeris Biopharma in the 4th quarter valued at $375,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

The firm has a 50 day simple moving average of $7.18 and a 200-day simple moving average of $7.62. The stock has a market capitalization of $985.56 million, a price-to-earnings ratio of -593.41 and a beta of 0.61.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.